Which brain-computer interface startup is growing the fastest?

Which brain-computer interface startup is growing the fastest right now?

Neuralink is the fastest-growing core brain-computer interface startup today because it is expanding chronic implanted users, clinical programs, countries and applications at the same time.

That answer becomes less obvious once we look beyond Neuralink. Precision Neuroscience now reports more than 95 implanted clinical-study patients and more than 15 active hospital partners. Science Corporation has reached European approval for PRIMA, putting it much closer to actual commercial sales. Synchron has implanted its BCI without open-brain surgery and is opening larger studies around that approach. Paradromics has moved from its first human recording to a long-term implant and, more recently, FDA approval for its study system to connect with compatible personal devices.

The companies are growing in different ways. For this article, we care most about repeatable growth in chronic human BCI use, then clinical reach, product expansion and the infrastructure needed to treat many more people. Funding helps us understand whether that growth can continue, but a large financing round by itself tells us very little.

On that basis, Neuralink still has the strongest overall case. Its latest official update put the participant population at 21, up from five around seven months earlier. During roughly the same stretch of development, the company expanded beyond basic computer control into robotic-arm control and speech restoration, while its clinical work spread outside the United States.

Precision beats Neuralink on total human research exposure. Science beats it on commercialization. Synchron may have the easier implantation model to scale. None currently combines as many forms of growth as Neuralink.

Company	Where it currently looks strongest	What keeps it from the overall lead
Neuralink	Chronic implanted-user growth and breadth	Still investigational
Precision Neuroscience	Human study exposure and hospital reach	Most patients are not chronic take-home BCI users
Synchron	Less invasive chronic implantation	Smaller disclosed implanted population
Science Corporation	Regulatory and commercial progress	PRIMA is a retinal neural prosthesis
Paradromics	Rapid move into chronic human testing	Still at the beginning of its implanted-user curve

If you want more recent data on this point, please see our latest neurotechnology market report.

Why is it so hard to say which BCI startup is growing fastest?

BCI growth is unusually hard to compare because “95 patients,” “21 participants” and “10 implants” can describe very different levels of real-world use.

Precision Neuroscience gives us the clearest example. Its website currently says Layer 7 has been implanted in more than 95 clinical-study patients. That number is much larger than Neuralink's latest official participant total.

But many Precision procedures happen around neurosurgery that the patient already needed. The Layer 7 array can be placed temporarily on the cortical surface, collect high-resolution data and then be removed. Precision's FDA-cleared cortical interface can now remain implanted for as long as 30 days, which makes these studies much more meaningful than a quick operating-room recording, but they still differ from a permanently implanted BCI used at home for months or years.

Neuralink, Synchron and Paradromics face a harder chronic-use test. Their participants live with implanted systems after the procedure, which brings long-term reliability, home use, follow-up and device durability into the comparison.

Science Corporation complicates things from the other direction. PRIMA has reached European approval and is heading toward commercial use, which is much further than the cortical-computer-control startups have gone. Yet PRIMA sits under the retina and restores visual information rather than decoding motor or speech intentions directly from the cortex.

So grabbing the largest number on each company’s website does not work. The type of patient exposure matters as much as the count.

Is Neuralink actually adding implanted BCI users quickly?

Yes. Neuralink has produced the fastest publicly confirmed rise in chronic implanted participants among the leading high-bandwidth BCI startups.

Neuralink's first human received the N1 implant in early 2024. By the middle of 2025, the company said five people with severe paralysis were using its technology. Its “Two Years of Telepathy” update then raised the official participant count to 21.

That means the disclosed population rose by 16 people from a base of five, or 320%, in roughly seven months. Percentage growth from such a small starting point can look more dramatic than it really is, so the absolute number matters too. Adding 16 chronic BCI participants is still a substantial jump in a field where previous intracortical research programs often accumulated participants one at a time over years.

Synchron says it has implanted ten people with its endovascular system. Paradromics only recently completed the first long-term Connexus implantation in its Connect-One study. Precision's much larger patient count belongs in a different category because of the temporary and extended-duration design of much of its clinical work.

We should also resist filling in the gaps ourselves. Neuralink has continued operating since announcing 21 participants, but its latest public materials do not give us a newer official total. So 21 remains the defensible number to use rather than an unofficial estimate.

Company	Best disclosed chronic-human comparison	What the number tells us
Neuralink	21 official participants	Fastest confirmed recent expansion
Synchron	10 implanted people	Longer clinical history, slower disclosed accumulation
Paradromics	First long-term Connect-One implant	Clinical curve has only just started
Precision Neuroscience	95+ clinical-study implants	Much broader human exposure, but not directly comparable chronic use

Is Precision Neuroscience actually growing faster than Neuralink?

Precision Neuroscience is growing faster in clinical reach, and the gap there is large enough that Neuralink should take it seriously.

Precision currently reports more than 95 implanted clinical-study patients and more than 15 active hospital partners. Its network includes major centers such as Mount Sinai, Penn Medicine, Mass General Brigham, Emory, Barrow, NYU, UChicago Medicine and Michigan Medicine.

The trajectory is stronger than the headline number alone suggests. Precision said it had passed 50 implanted patients in 2025. Reaching more than 95 means its cumulative clinical exposure subsequently grew by at least about 90%.

Its approach makes that pace possible. Layer 7 is an ultrathin array placed on the brain's surface rather than pushed into brain tissue. Precision can therefore learn from patients undergoing neurosurgical procedures without requiring every study use to begin with a standalone permanent BCI operation.

The company has also moved beyond short intraoperative demonstrations. FDA clearance now allows the Layer 7 cortical interface to remain implanted for up to 30 days for recording, monitoring and stimulation. That gives Precision much longer windows for collecting data and testing tasks while keeping a relatively conservative surgical design.

We would still put Neuralink ahead when the question is growth in chronic, take-home BCI users. Precision, though, has built the strongest hospital-distribution engine of any startup in this group. If that network carries over to a fully implantable wireless system, the ranking could change quickly.

If you want more recent data on this point, please see our latest neurotechnology market report.

Has Precision Neuroscience turned its hospital growth into something commercially useful?

Yes. Precision Neuroscience has already converted part of its clinical momentum into an FDA-cleared product and a relationship with Medtronic.

The FDA cleared the Layer 7 Cortical Interface for temporary recording, monitoring and stimulation on the brain's surface, with implantation durations of up to 30 days. Precision's complete wireless BCI remains investigational, so we should not treat this as approval of the whole system.

Still, the clearance gives Precision something Neuralink, Synchron and Paradromics currently lack for their main BCI platforms: a component that hospitals can legally use commercially for a defined clinical purpose in the United States.

The Medtronic partnership strengthens that route. The two companies are working to integrate Layer 7 with Medtronic's StealthStation neurosurgical platform. For Precision, getting its technology into workflows around an established neurosurgical system could be more useful than adding another research hospital from scratch.

Precision has also been building the team needed to move beyond experiments. Recent hires include senior leadership around AI, data, medical affairs and implant engineering. Taken together with FDA clearance and the hospital network, the company looks increasingly like a medical-device business preparing for repeat deployment.

That is why Precision is Neuralink's closest competitor for growth today. Its numbers come from a different kind of BCI use, but they are no longer just laboratory demonstrations.

Could Synchron grow faster because its BCI avoids open-brain surgery?

Synchron has the clearest procedural advantage in the BCI race, and that could eventually matter more than Neuralink's current participant lead.

Synchron delivers the Stentrode through the jugular vein and positions it inside a blood vessel near the motor cortex. The procedure resembles catheter-based vascular medicine far more than conventional brain surgery and does not require cutting through the skull to place electrodes into brain tissue.

The company chose that design specifically with scale in mind. Synchron points to cardiology, where catheter labs routinely handle huge numbers of stents, pacemakers and other interventions. Its bet is straightforward: if BCI implantation can use familiar vascular infrastructure, hospitals may eventually adopt it much more easily.

The clinical population remains smaller for now. Synchron has reported ten implanted people, including six participants in its U.S. COMMAND study. The company has since opened or prepared newer studies in the United States, Canada and Australia.

Those newer trials give Synchron a chance to show whether its procedural advantage translates into faster recruitment. That is the number to watch, not another demonstration of a participant controlling consumer technology.

If Synchron starts adding patients across several hospitals without needing a specialized neurosurgical robot or open-brain procedure, its growth story becomes much stronger. Today, Neuralink has the steeper confirmed chronic-user curve. Synchron may have the cleaner route to scaling that curve later.

Is Science Corporation already ahead because PRIMA can actually be sold?

Science Corporation is ahead on commercialization, and this is the strongest argument against automatically calling Neuralink the BCI leader on every measure.

PRIMA received European regulatory approval for treating vision loss associated with advanced age-related macular degeneration. That moves Science into a stage the main cortical BCI startups have not reached: preparing to sell an implanted neural device for an approved medical use.

The clinical evidence is also much larger than a handful of feasibility cases. Science's European program studied 38 patients with advanced geographic atrophy. The New England Journal of Medicine reported meaningful gains in visual acuity for most participants who completed follow-up, including an ability to read letters, numbers and words that had previously been inaccessible.

Science raised $230 million earlier in 2026 partly to fund PRIMA commercialization and expand testing into additional retinal diseases. The financing makes more sense when viewed beside the regulatory progress: this money is arriving as the company moves toward sales rather than years before a potential product.

The reason we do not put Science first in the core BCI ranking is technological scope. PRIMA is a retinal implant paired with external glasses. It bypasses damaged photoreceptors and stimulates remaining retinal cells. Neuralink, Synchron, Precision and Paradromics are building systems that decode brain activity directly for communication or control.

If the title were “Which neural-interface startup is closest to becoming a real medical-device business?”, Science would currently have the best answer. For brain-to-computer control, Neuralink remains ahead.

If you want more recent data on this point, please see our latest neurotechnology market report.

Is Paradromics finally becoming a serious Neuralink competitor?

Paradromics has made its biggest clinical jump yet, and it now belongs in the main BCI race rather than in the promising-preclinical category.

The change happened in stages. Paradromics first demonstrated a short human recording with Connexus during epilepsy surgery. The FDA then approved the Connect-One early-feasibility study for long-term use of the fully implanted system.

The first chronic Connect-One implantation followed at University of Michigan Health. Connexus uses a high-density intracortical array to capture neural activity and sends those signals through an implanted chest transceiver to an external receiver. The study is testing speech restoration and computer control in people with severe motor impairment.

More recently, Paradromics received another FDA approval that expands what trial participants can eventually connect to. After an agreed testing process, compatible laptops, tablets and phones can be added without Paradromics needing separate FDA approval for every device.

That may sound like a small software detail, but it addresses a practical weakness of many experimental BCIs. A participant gains much more from controlling the devices already used every day than from operating a closed demonstration computer supplied by a research team.

Paradromics is also screening potential participants through University of Michigan, UC Davis and Massachusetts General Hospital. The company still has far fewer chronic implants than Neuralink, but its clinical program is moving much faster than it was a year ago.

Which BCI startup is expanding into the most useful real-world applications?

Neuralink currently has the broadest active product expansion among the cortical BCI startups.

Telepathy began with digital control: moving a cursor, using computers and interacting with software through decoded motor intent. The company then added CONVOY, which extends control to an assistive robotic arm.

That step changes the practical value of the system. Controlling a laptop can restore communication and digital independence; controlling a robotic arm can help with physical tasks such as feeding or manipulating objects.

Neuralink is also developing VOICE for people with severe speech impairment. The study is designed to turn neural activity associated with intended speech into text or spoken output. So the same basic N1 platform is being pushed across digital control, physical assistance and communication.

Synchron has also connected its system to mainstream consumer platforms, including Apple devices and Amazon's Alexa ecosystem, which is useful because it shows how an implanted BCI can fit into technology people already know. Paradromics' newly approved personal-device pathway points in the same direction.

What gives Neuralink the edge today is breadth. Its clinical roadmap already spans several distinct human abilities rather than a single narrow endpoint. It is starting to look like a BCI platform, not one medical application.

Which BCI startup has the strongest regulatory position right now?

Science Corporation has the strongest commercial regulatory position, while Precision Neuroscience has the strongest U.S. clearance among the cortical-interface startups.

Science can move toward selling PRIMA in Europe following regulatory approval. That is the highest regulatory rung reached by any company in this comparison.

Precision's Layer 7 cortical interface has FDA 510(k) clearance for defined temporary uses of up to 30 days. Its complete chronic wireless BCI is still being developed, but the clearance gives Precision a real foothold inside hospitals today.

Neuralink, Synchron and Paradromics remain in investigational clinical programs for their main implanted systems. That does not mean their FDA progress is weak. Neuralink has expanded its clinical work into robotic control and speech. Synchron has completed major safety follow-up in COMMAND and is moving into additional studies. Paradromics went from an IDE approval to its first chronic implant and then secured permission for compatible personal computing devices.

The order depends on what we mean by regulatory progress. Science is closest to ordinary commercial medicine. Precision has the clearest cleared cortical product. Neuralink has the largest expanding chronic BCI program.

For an article about growth rather than regulatory sophistication, we still give more weight to the size and speed of the clinical program. Science and Precision are the reason “Neuralink is ahead” needs a precise definition.

If you want more recent data on this point, please see our latest neurotechnology market report.

Is all this BCI funding producing real growth or just bigger valuations?

The biggest BCI rounds are increasingly attached to clinical expansion, although some companies still have far more money than human evidence.

Neuralink's $650 million Series E is the clearest example. By the time the company announced it, five people were already using its implants, trials had expanded internationally and the product roadmap had moved beyond cursor control. The next official participant update showed a much larger clinical population.

Science's $230 million Series C is even closer to commercial activity. The company said the money would support PRIMA commercialization and additional trials at a point when European approval was already within reach.

Synchron's latest large financing is intended to support bigger clinical programs, commercialization work and a next generation of its endovascular platform. Here again, the important test will be patient recruitment rather than the valuation attached to the round.

Merge Labs sits at the other end of the spectrum. It launched with roughly $250 million of funding and ambitious work around less invasive neural interfaces, molecular approaches and ultrasound. OpenAI participated in the financing. Yet Merge does not have a comparable implanted-human program today.

Money becomes a useful growth metric only when another part of the business moves with it. Neuralink currently has the strongest combination because capital, human implantation and product expansion have all accelerated within the same development cycle.

Company	Major recent capital	What we can already see happening
Neuralink	$650M	Clinical and product expansion
Science Corporation	$230M	Commercialization and broader trials
Synchron	$200M	Larger studies and platform development
Merge Labs	About $250M at launch	Research build-out; little comparable human data yet

Can Neuralink's surgery actually scale to thousands of BCI users?

We still do not know whether Neuralink's implantation model will work at mass scale, and this is the biggest weakness in its current lead.

Neuralink inserts flexible electrode threads into brain tissue using the R1 surgical robot. That design aims for high-quality neural recordings while automating a procedure too delicate for ordinary manual insertion.

The company has already shown that the process can be repeated across a growing number of participants. Reaching 21 officially announced participants is meaningful because this is a chronic intracortical system rather than a brief research placement.

Thousands of procedures would create a very different challenge. Neuralink would need enough robots, trained surgical teams, clinical sites, manufacturing capacity and post-operative support to make implantation routine rather than exceptional.

Synchron avoids part of that problem by using a catheter-based procedure. Precision reduces tissue penetration by placing Layer 7 on the cortical surface. Those designs sacrifice or alter different aspects of neural access, but they make the deployment question harder for Neuralink.

The next few dozen implants will tell us more than another impressive cursor-speed demo. If Neuralink can spread implantation across more hospitals while keeping outcomes consistent, its surgical model starts looking genuinely scalable. If expansion remains concentrated around a small group of specialized teams, Synchron and Precision gain ground.

Is Neuralink's more invasive BCI design becoming a problem?

Neuralink's invasiveness has not stopped its growth so far, but it remains the most obvious way competitors could eventually beat it.

The N1 system gets close to neurons by inserting very thin threads into brain tissue. That can produce richer signals for high-bandwidth control, but chronic intracortical devices face mechanical and biological problems that surface or vascular systems try to avoid.

Neuralink's first participant showed one version of that risk when some electrode threads retracted after surgery. Neuralink adjusted its decoding software and the participant continued using the system, so the episode did not derail the trial. It did show that successful implantation is only the beginning of the engineering problem.

Precision takes a different route by keeping electrodes on the cortical surface. Synchron stays inside a blood vessel. Paradromics, like Neuralink, accepts intracortical penetration because it wants high-data-rate access to individual-neuron activity.

There is no free design choice here. Less invasive systems may be easier to implant but could face limits on signal richness or electrode location. Penetrating arrays offer stronger access at the cost of a tougher long-term interface with brain tissue.

Neuralink is growing despite choosing the difficult end of that trade-off. Whether it can keep doing so at much larger scale remains one of the most important open questions in the industry.

Could Precision, Synchron or Paradromics overtake Neuralink soon?

Precision Neuroscience has the clearest near-term route to catching Neuralink, while Synchron has the strongest chance of changing the race later through easier implantation.

Precision already has the hospital network. More than 15 active partners give it many places to collect data, train clinicians and build familiarity with Layer 7. Its FDA clearance also lets hospitals use the cortical interface for a defined clinical purpose without waiting for the full chronic BCI program to mature.

Synchron's route is different. If its upcoming studies recruit quickly across several countries, the company could show that avoiding open-brain surgery produces a genuine enrollment advantage. A catheter-delivered BCI becomes particularly interesting once trials need tens and eventually hundreds of participants.

Paradromics is further behind in absolute numbers but moving quickly. Its first long-term implant, multi-site screening and recent FDA expansion to personal devices have all happened within a relatively short period. We would pay much more attention if that first implant becomes a repeatable series across University of Michigan, UC Davis and Massachusetts General.

Science Corporation could also change the comparison through revenue. Once PRIMA starts generating meaningful commercial sales, treating “growth” as purely a clinical-enrollment contest becomes harder to defend.

Neuralink has a real lead, not an unbeatable one. Precision is already pressing it on institutional scale, Synchron on surgical simplicity, Science on commercialization and Paradromics on high-bandwidth clinical competition.

What would make Neuralink lose the fastest-growing BCI title?

Neuralink should lose the title as soon as one competitor turns a narrower advantage into faster repeatable human deployment.

For Precision, the decisive change would be converting its large hospital footprint into a chronic take-home BCI program that starts adding permanent users quickly.

For Synchron, we would want to see its catheter-based model fill larger studies across multiple hospitals noticeably faster than Neuralink can expand robotic brain surgery.

Paradromics needs repeated long-term Connexus implants. One implant proves entry into the clinic; several sites adding patients would show that a real clinical machine is starting to form.

Science Corporation has a completely different path. Meaningful PRIMA sales would make it difficult to ignore commercial growth even though its retinal interface sits outside the narrowest definition of a brain-to-computer implant.

Neuralink could also lose through its own execution. Slower recruitment, surgical bottlenecks, reliability problems or difficulty adding clinical sites would weaken the strongest parts of its current case.

These are cleaner tests than vague talk about “momentum.” We can watch implanted users, sites, repeat procedures and commercial treatments and change the ranking when those numbers change.

So which brain-computer interface startup is growing the fastest today?

Neuralink is still the fastest-growing core BCI startup today, and the gap is clearest when we focus on chronic implanted users plus expansion of what those users can actually do.

Its latest official participant figure represents a sharp jump from the five people disclosed earlier in the program. The company has also expanded from computer control into robotic assistance and speech restoration while taking its clinical work into more countries and hospitals.

Precision Neuroscience deserves the closest scrutiny. As seen above, its more than 95 clinical-study patients and network of over 15 hospital partners give it far more human exposure than Neuralink. Its FDA-cleared cortical array and Medtronic partnership could eventually turn that reach into a faster commercial rollout.

Synchron is the company we would worry about most if open-brain surgery becomes the main bottleneck. Its endovascular approach fits a much more familiar medical workflow, although the disclosed implanted-user population remains smaller today.

Science Corporation is already winning a different race. European approval for PRIMA puts it ahead on commercialization, and revenue could soon become a metric that the research-stage cortical BCI companies cannot match.

Paradromics has become much more credible lately too. Its first long-term implant and fresh FDA approval for compatible personal devices show that Connexus is finally moving from technical promise into everyday-use questions.

Put those companies on one scoreboard, and Neuralink comes first for now. The reason is simple: it has been adding chronic users quickly while widening both the clinical footprint and the jobs its implant is being asked to perform. No competitor has yet matched that combination.

If you want more recent data on this point, please see our latest neurotechnology market report.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.